Suppr超能文献

IgG4 相关眼病患者眼外表现的危险因素及治疗结局。

Risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease.

机构信息

Department of Ophthalmology, Korean Armed Forces Capital Hospital, Seongnam, Korea.

Department of Ophthalmology, Hallym University Sacred Heart Hospital, Anyang, Korea.

出版信息

Br J Ophthalmol. 2018 Jun;102(6):736-741. doi: 10.1136/bjophthalmol-2017-310584. Epub 2017 Sep 28.

Abstract

BACKGROUND/AIM: To analyse the clinical risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease (IgG4-ROD) in Korea.

METHODS

We retrospectively reviewed medical records of 42 patients diagnosed with IgG4-ROD confirmed by a surgical biopsy during the 7-year period, between January 2009 and March 2015, at three tertiary referral centres in Korea. Data regarding patients' demographics, clinical characteristics and radiological findings were obtained. The relapse rate was compared between systemic steroids only and combined immunosuppressant therapy.

RESULTS

The mean patient age was 55.2 years (male:female ratio, 1:1). Based on the primary orbital structure affected, the IgG4-RODs were classified as dacryoadenitis (52.4%), orbital soft tissue inflammation (21.4%), trigeminal nerve involvement (11.9%) and myositis (9.5%). Extraophthalmic involvement (n=21) was associated with bilateral involvement (p=0.004), longer symptom duration (p=0.033) and a higher serum IgG4 level (p=0.034). Initial treatment regimens included attentive observation (n=7), prednisolone alone (n=22) and prednisolone plus immunosuppressive agent (n=13). During follow-up (mean, 24 months), 13 patients (37.1%) experienced relapse. In the extraophthalmic involvement group, steroid therapy alone resulted in a significantly higher relapse rate than combined immunosuppressant treatment (p=0.028).

CONCLUSION

Bilateral involvement, longer symptom duration and higher IgG4 levels were significant risk factors for extraophthalmic involvement in Korean patients with IgG4-ROD. In patients with an extraophthalmic involvement, prednisolone combined with an immunosuppressive agent was more effective for preventing recurrence than prednisolone alone.

摘要

背景/目的:分析韩国 IgG4 相关眼病(IgG4-ROD)患者的眼部外表现累及的临床危险因素及治疗结局。

方法

我们回顾性分析了 2009 年 1 月至 2015 年 3 月期间在韩国三家三级转诊中心经手术活检确诊为 IgG4-ROD 的 42 例患者的病历资料。收集患者的人口统计学、临床特征和影像学检查结果等数据。比较了仅使用全身性皮质类固醇激素与联合使用免疫抑制剂治疗的复发率。

结果

患者平均年龄为 55.2 岁(男女比例 1:1)。根据受影响的主要眼眶结构,IgG4-ROD 分为泪腺炎(52.4%)、眼眶软组织炎症(21.4%)、三叉神经受累(11.9%)和肌炎(9.5%)。眼部外表现累及(n=21)与双侧受累(p=0.004)、更长的症状持续时间(p=0.033)和更高的血清 IgG4 水平(p=0.034)相关。初始治疗方案包括密切观察(n=7)、单独使用泼尼松龙(n=22)和泼尼松龙联合免疫抑制剂(n=13)。在随访期间(平均 24 个月),13 例患者(37.1%)复发。在外表现累及组中,单独使用皮质类固醇激素治疗的复发率明显高于联合免疫抑制剂治疗(p=0.028)。

结论

在韩国 IgG4-ROD 患者中,双侧受累、症状持续时间较长和 IgG4 水平较高是眼部外表现累及的显著危险因素。对于有眼部外表现累及的患者,泼尼松龙联合免疫抑制剂治疗比单独使用泼尼松龙更能有效预防复发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验